Brief: Onxeo reports positive data for Livatag

Valerio Therapeutics SA

19/04/2016 06:52

April 19(Reuters) - Onxeo SA  C4X.PA : 
    * Reported on Monday the final data from a study aiming to 
confirm the mechanism of action of Livatag  
    * Results demonstrated that the bio-distribution of 
oxorubicin Transdrug (Livatag) nanoparticles showed a 
preferential affinity for the liver and an increased exposure in 
plasma compared to free doxorubicin 
 
     
      
 Source text for Eikon:  urn:newsml:reuters.com:*:nBwF62JPa 
     
 Further company coverage:  C4X.PA   
    
 
 
 (Gdynia Newsroom) 
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 698 3920;))